You are here

  • Home
  • Archive
  • Volume 15, Issue Suppl 3
  • First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB–IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival

Article info

Article menu
Download PDFPDF
Articles
First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB–IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival

Authors

Citation

KRISTENSEN GB, VERGOTE I, STUART G, et al
First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB–IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival
International Journal of Gynecologic Cancer 2005;15:221.

Publication history

  • First published November 1, 2005.
Online issue publication 
December 14, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2005 IGCS